Omnicell, Inc. (OMCL)
Stock Price:
$68.59 USD
0.55 (0.81%)
Updated Aug 7, 2020 4:00 PM EDT - Market closed
Key Info
| Market Cap |
2.93B |
| Revenue (ttm) |
906.40M |
| Net Income (ttm) |
49.09M |
| Shares Out |
42.76M |
| EPS (ttm) |
1.13 |
| PE Ratio |
60.70 |
| Forward PE |
31.85 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Aug 7, 2020 |
| Last Price |
$68.59 |
| Previous Close |
$68.04 |
| Change ($) |
0.55 |
| Change (%) |
0.81% |
| Day's Open |
67.96 |
| Day's Range |
67.30 - 68.60 |
| Day's Volume |
168,577 |
| 52-Week Range |
54.24 - 94.85 |
More Stats
| Market Cap |
2.93B |
| Enterprise Value |
2.85B |
| Earnings Date (est) |
Oct 22, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
42.76M |
| Float |
41.94M |
| EPS (basic) |
1.18 |
| EPS (diluted) |
1.13 |
| FCF / Share |
2.37 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
1.65% |
| FCF Yield |
3.45% |
| Payout Ratio |
n/a |
| Shares Short |
2.53M |
| Short Ratio |
8.59 |
| Short % of Float |
8.73% |
| Beta |
1.00 |
| PE Ratio |
60.70 |
| Forward PE |
31.85 |
| P/FCF Ratio |
29.02 |
| PS Ratio |
3.24 |
| PB Ratio |
3.28 |
| Revenue |
906.40M |
| Operating Income |
51.99M |
| Net Income |
49.09M |
| Free Cash Flow |
101.06M |
| Net Cash |
86.89M |
| Net Cash / Share |
2.03 |
| Gross Margin |
48.20% |
| Operating Margin |
5.74% |
| Profit Margin |
5.40% |
| FCF Margin |
11.15% |
| ROA |
3.20% |
| ROE |
5.91% |
| ROIC |
10.50% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (9)
| Buy |
6 |
| Overweight |
0 |
| Hold |
3 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$79.78*
(16.31% upside)
Low
59.0
Current: $68.59
High
90.0
Target: 79.78
*Average 12-month price target from 9 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|
| Revenue | 897 | 787 | 713 | 696 | 485 | 441 | 381 | 314 | 246 | 222 |
| Revenue Growth | 13.94% | 10.47% | 2.41% | 43.62% | 9.9% | 15.85% | 21.19% | 27.9% | 10.4% | - |
| Gross Profit | 437 | 372 | 319 | 317 | 248 | 234 | 203 | 171 | 136 | 118 |
| Operating Income | 78.35 | 44.39 | 11.15 | 21.41 | 45.19 | 49.58 | 35.30 | 27.13 | 16.22 | 9.53 |
| Net Income | 61.34 | 37.73 | 30.52 | 9.76 | 30.76 | 30.52 | 23.98 | 16.18 | 10.39 | 4.89 |
| Shares Outstanding | 41.46 | 39.24 | 37.48 | 36.16 | 35.86 | 35.65 | 34.74 | 33.31 | 33.12 | 32.65 |
| Earnings Per Share | 1.43 | 0.93 | 0.79 | 0.26 | 0.84 | 0.83 | 0.67 | 0.47 | 0.30 | 0.15 |
| EPS Growth | 53.76% | 17.72% | 203.85% | -69.05% | 1.2% | 23.88% | 42.55% | 56.67% | 100% | - |
| Operating Cash Flow | 145 | 104 | 24.83 | 49.90 | 38.49 | 65.16 | 55.26 | 39.48 | 31.24 | 20.60 |
| Capital Expenditures | -61.66 | -54.37 | -30.38 | -27.79 | -19.67 | -22.28 | -20.10 | -20.15 | -12.88 | -9.10 |
| Free Cash Flow | 83.34 | 49.59 | -5.55 | 22.11 | 18.81 | 42.89 | 35.17 | 19.34 | 18.37 | 11.50 |
| Cash & Equivalents | 127 | 67.19 | 32.42 | 54.49 | 82.22 | 126 | 105 | 62.31 | 200 | 184 |
| Total Debt | 101 | 135 | 210 | 254 | - | - | - | - | - | - |
| Net Cash / Debt | 26.54 | -68.23 | -178 | -200 | 82.22 | 126 | 105 | 62.31 | 200 | 184 |
| Assets | 1,241 | 1,081 | 1,016 | 935 | 579 | 560 | 493 | 442 | 364 | 343 |
| Liabilities | 396 | 402 | 462 | 503 | 176 | 170 | 144 | 134 | 80.94 | 78.01 |
| Book Value | 845 | 680 | 554 | 432 | 402 | 390 | 349 | 308 | 283 | 265 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Omnicell, Inc. |
| Country |
United States |
| Employees |
2,780 |
| CEO |
Randall A. Lipps |
Stock Information
| Ticker Symbol |
OMCL |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Health Information Services |
| Unique Identifier |
NASDAQ: OMCL |
| IPO Date |
August 7, 2001 |
Description
Omnicell, Inc., together with its subsidiaries, provides medication management automation solutions and adherence tools for healthcare systems and pharmacies worldwide. The company offers central pharmacy automation solutions, including automated storage and retrieval systems, such as XR2 Automated Central Pharmacy System, a building block of autonomous pharmacy vision; IV compounding robots and workflow management systems; inventory management software; and controlled substance management systems. It also provides point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; Omnicell Interface Software that offers interface and integration between its medication-use products or supply products, and a healthcare facility's in-house information management systems; and robotic dispensing systems used in hospitals and retail pharmacies for handling the stocking and retrieval of boxed medications. In addition, the company provides single dose automation solutions to fill and label for incoming prescriptions; medication blister card packaging and packaging supplies to enhance medication adherence in non-acute care settings; automated systems to help pharmacies in filling its multimed adherence packaging based on individual patient medication orders; and semi-automated filling equipment for the long-term care institutional pharmacy. Further, it offers Omnicell Patient Engagement, a web-based nexus of solutions; and patient communication tools, such as interactive voice response, outbound communications, and mobile app. The company was formerly known as Omnicell Technologies, Inc. and changed its name to Omnicell, Inc. in 2001. Omnicell, Inc. was founded in 1992 and is headquartered in Mountain View, California.